Synthelabo's devices sales growth estimated at 7%:
This article was originally published in Clinica
Executive Summary
Sales at Synthelabo's pacemakers and catheters divisions are estimated to grow 7% over the next five years, concludes a report by US analysts Morgan Stanley. They expect "no dramatic developments" in Ela Medical's pacemaker and ECG business over the next few years. Porges' catheter and urology products division reported sales of Fr 173 million ($36 million) in 1994, while Ela Medical posted Fr 489 million revenues for the year. Medical devices represented around 8% of the company's revenues in 1994.
You may also be interested in...
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.